Bondronat: Uses, Dosage & Side Effects
A bisphosphonate medication containing ibandronic acid used to prevent skeletal events in breast cancer patients with bone metastases
Bondronat (ibandronic acid) is a potent third-generation bisphosphonate available as 50 mg film-coated tablets. It is primarily prescribed for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. Ibandronic acid works by inhibiting osteoclast-mediated bone resorption, reducing the excessive bone breakdown caused by metastatic tumor cells. Bondronat is also available as an intravenous formulation and, under the brand name Bonviva (or Boniva), is used at lower doses for the treatment of postmenopausal osteoporosis. The oral formulation requires careful administration — taken on an empty stomach with plain water while remaining upright for at least 60 minutes — to ensure proper absorption and to minimize the risk of esophageal irritation.
Quick Facts: Bondronat
Key Takeaways
- Bondronat (ibandronic acid 50 mg) is a bisphosphonate specifically indicated for preventing skeletal events in breast cancer patients with bone metastases.
- The standard oral dose is 50 mg once daily, taken on an empty stomach with a full glass of plain water, followed by remaining upright for at least 60 minutes.
- Ibandronic acid inhibits osteoclast-mediated bone resorption, reducing pathological fractures and the need for radiotherapy or surgical intervention to bone.
- Rare but serious risks include osteonecrosis of the jaw (ONJ), atypical femur fractures, and esophageal ulceration — dental evaluation is recommended before starting treatment.
- Treatment duration is determined by your oncologist based on ongoing clinical benefit, and is not subject to the “drug holiday” approach used in osteoporosis therapy.
What Is Bondronat and What Is It Used For?
Bondronat belongs to a group of medications called bisphosphonates, specifically the third-generation nitrogen-containing bisphosphonates. These drugs work by binding to the mineral component of bone (hydroxyapatite) and selectively inhibiting the activity of osteoclasts — the cells responsible for breaking down bone tissue. In the context of bone metastases, osteoclasts are excessively stimulated by tumor-derived factors, leading to accelerated bone destruction, pathological fractures, bone pain, and hypercalcemia. By suppressing osteoclast function, ibandronic acid reduces these skeletal complications and helps preserve bone integrity.
The primary indication for Bondronat 50 mg tablets is the prevention of skeletal events in patients with breast cancer and bone metastases. Skeletal events — also called skeletal-related events (SREs) — include pathological fractures, the need for radiotherapy to bone, orthopedic surgical interventions, and spinal cord compression. These events significantly impact quality of life and can lead to increased morbidity and mortality. Clinical trials, including the pivotal MF4434 and MF4265 studies, have demonstrated that oral ibandronic acid 50 mg daily significantly reduces the rate of skeletal events and extends the time to the first skeletal event compared to placebo in breast cancer patients with bone metastases.
Ibandronic acid is also available in an intravenous (IV) formulation (6 mg infusion every 3–4 weeks) under the Bondronat brand. The IV route may be preferred for patients who cannot tolerate oral bisphosphonates, have difficulty complying with the strict dosing requirements, or have significant gastrointestinal disorders. At lower doses, ibandronic acid is also marketed under different brand names (Bonviva in Europe, Boniva in the United States) for the treatment and prevention of postmenopausal osteoporosis, where it is given as 150 mg once monthly orally or 3 mg IV every 3 months.
The mechanism of action of ibandronic acid at the molecular level involves inhibition of farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway within osteoclasts. This prevents the prenylation of small GTPase signaling proteins (such as Ras, Rho, and Rac) that are essential for osteoclast function, attachment to bone, and survival. The result is osteoclast apoptosis (programmed cell death) and a marked reduction in bone resorption. Ibandronic acid is one of the most potent bisphosphonates in terms of its affinity for bone mineral and its inhibitory potency against FPPS.
In addition to its anti-resorptive effects, preclinical research has suggested that ibandronic acid may have anti-tumor properties, including inhibition of tumor cell adhesion to bone matrix, reduction of tumor cell invasion, and induction of tumor cell apoptosis. However, these effects have not been conclusively demonstrated in clinical settings, and Bondronat is not approved as an anti-cancer agent. Its clinical benefit is established for skeletal protection rather than direct anti-tumor activity.
What Should You Know Before Taking Bondronat?
Bondronat is not suitable for everyone. Before starting treatment, your oncologist will evaluate your medical history, current medications, kidney function, and overall health to determine whether this medication is appropriate for you. Because patients with bone metastases often receive multiple concurrent treatments (chemotherapy, hormonal therapy, radiotherapy), it is especially important to consider potential interactions and cumulative toxicities.
Contraindications
You should not take Bondronat if any of the following apply:
- You are allergic to ibandronic acid or any of the other ingredients in the tablet (lactose monohydrate, povidone, microcrystalline cellulose, crospovidone, stearic acid, colloidal anhydrous silica)
- You have esophageal abnormalities such as stricture (narrowing) or achalasia (inability of the esophagus to move food to the stomach)
- You are unable to stand or sit upright for at least 60 minutes after taking the tablet
- You have low blood calcium levels (hypocalcemia) — this must be corrected before starting Bondronat
- You have severe kidney impairment (creatinine clearance below 30 ml/min)
Warnings and Precautions
Talk to your oncologist or pharmacist before taking Bondronat if any of the following conditions apply to you:
- Kidney problems — kidney function should be monitored regularly during treatment. Dose adjustment or discontinuation may be necessary if kidney function deteriorates. Serum creatinine should be checked before each IV dose, and renal function should be assessed periodically with oral treatment.
- Swallowing or digestive problems — including Barrett’s esophagus, difficulty swallowing, gastritis, duodenitis, or active upper gastrointestinal disease. The IV formulation may be more appropriate for patients with significant GI disease.
- Low calcium or vitamin D levels — hypocalcemia and other disturbances of bone and mineral metabolism must be effectively treated before starting bisphosphonate therapy. Adequate intake of calcium and vitamin D is important for all patients receiving Bondronat.
- Lactose intolerance — Bondronat tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
- Concurrent chemotherapy or anti-angiogenic agents — these may increase the risk of osteonecrosis of the jaw when used together with bisphosphonates.
A dental examination with appropriate preventive dentistry should be considered before starting Bondronat treatment, particularly in oncology patients with concomitant risk factors such as cancer, chemotherapy, radiotherapy, corticosteroids, or poor oral hygiene. Osteonecrosis of the jaw (ONJ) — a serious condition involving exposed bone in the jaw that fails to heal — has been reported in patients treated with bisphosphonates, primarily in the cancer population. While on treatment, patients should avoid invasive dental procedures if possible. Dental surgery may exacerbate the condition. Inform your dentist that you are taking Bondronat before any dental procedures.
Irritation, inflammation, or ulceration of the esophagus can occur with oral bisphosphonate use, particularly if patients do not follow the strict dosing instructions. The risk is higher than with some other bisphosphonates because the daily 50 mg dose means repeated esophageal exposure. Stop taking Bondronat and contact your doctor immediately if you experience difficulty swallowing, pain on swallowing, retrosternal (behind the breastbone) pain, or new or worsening heartburn.
Hypocalcemia has been reported in patients treated with Bondronat, particularly in the oncology setting where patients may have additional risk factors for low calcium (such as poor nutritional status, extensive bone disease, or concurrent medications that lower calcium). Symptoms of hypocalcemia include numbness or tingling in the fingers, toes, or around the mouth, muscle spasms, and seizures. Calcium and vitamin D supplementation is generally recommended during treatment.
Pregnancy and Breastfeeding
Bondronat should not be taken during pregnancy or breastfeeding. In animal studies, bisphosphonates have been shown to cross the placenta and cause adverse effects on fetal development, including skeletal abnormalities. There are no adequate human data on use during pregnancy. Because bisphosphonates are incorporated into bone matrix and released slowly over years, there is a theoretical risk of fetal harm if pregnancy occurs even after discontinuation. Women of childbearing potential should use effective contraception during treatment and discuss the potential risks with their healthcare provider.
It is not known whether ibandronic acid is excreted in human breast milk. In animal studies, low levels of ibandronic acid were detected in breast milk. Because of the potential for adverse effects in the nursing infant, breastfeeding should be discontinued during Bondronat treatment.
Driving and Using Machines
Based on the pharmacodynamic profile and reported adverse reactions, Bondronat is expected to have no or negligible influence on the ability to drive and use machines. However, individual responses may vary. If you experience dizziness, blurred vision, or bone pain that affects your ability to concentrate, avoid driving or operating machinery until the symptoms resolve.
How Does Bondronat Interact with Other Drugs?
Drug interactions are a particularly important consideration for Bondronat because many patients with breast cancer and bone metastases receive complex multi-drug regimens. The most clinically significant interactions involve substances that interfere with the already very low oral bioavailability of ibandronic acid (approximately 0.6% under fasting conditions). Even small reductions in absorption can render the drug ineffective.
It is essential to inform your oncologist and pharmacist about all medications you are taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins. Below is a summary of the most important interactions:
Major Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Calcium supplements | Significantly reduces ibandronic acid absorption by forming insoluble complexes in the GI tract | Take calcium at least 60 minutes after Bondronat (preferably with a later meal) |
| Antacids (aluminum, magnesium hydroxide) | Substantially reduces ibandronic acid absorption due to polyvalent cation binding | Wait at least 60 minutes after Bondronat before taking antacids |
| Iron supplements | May reduce ibandronic acid absorption through chelation | Take iron supplements at least 60 minutes after Bondronat or at a different time of day |
| NSAIDs (ibuprofen, naproxen, aspirin) | Increases risk of gastrointestinal irritation, ulceration, and bleeding | Use with caution; discuss with your oncologist if you need regular NSAID use |
| Aminoglycosides (gentamicin, tobramycin) | May enhance the calcium-lowering effect; both agents decrease serum calcium levels | Monitor calcium levels closely when used concurrently |
| Thalidomide | May increase the risk of renal impairment in multiple myeloma patients | Monitor renal function carefully when these drugs are used together |
Minor Interactions
Proton pump inhibitors (PPIs) such as omeprazole and pantoprazole may theoretically affect ibandronic acid absorption due to changes in gastric pH. However, clinical data have not demonstrated a clinically significant reduction in efficacy. Many oncology patients take PPIs for chemotherapy-related gastric symptoms, and this combination is generally considered acceptable.
Chemotherapy agents: No specific pharmacokinetic interactions have been identified between ibandronic acid and commonly used breast cancer chemotherapy regimens (anthracyclines, taxanes, capecitabine). Ibandronic acid is not metabolized by cytochrome P450 enzymes and does not inhibit or induce hepatic CYP isoenzymes. This favorable pharmacokinetic profile means that drug-drug interactions at the metabolic level are unlikely.
Hormonal therapy: Concurrent use of ibandronic acid with aromatase inhibitors (letrozole, anastrozole, exemestane) or tamoxifen is common in clinical practice and is not associated with significant pharmacokinetic interactions. In fact, the combination of bisphosphonates with aromatase inhibitors may be beneficial, as aromatase inhibitors are known to accelerate bone loss.
After swallowing your Bondronat tablet, wait at least 60 minutes before taking any other medication, eating, or drinking anything other than plain water. This strict timing requirement distinguishes the Bondronat 50 mg oncology dose from some other bisphosphonates that require only 30 minutes of fasting. The longer fasting period is critical for adequate absorption of the daily oncology dose.
What Is the Correct Dosage of Bondronat?
Always take Bondronat exactly as prescribed by your oncologist. The dosage for bone metastases differs from the dosages used for osteoporosis (which uses different brand names and lower or less frequent doses). Do not change your dose without consulting your healthcare provider.
Adults
Bone Metastases from Breast Cancer (Oral)
Standard dose: 50 mg once daily, taken every day without interruption.
The 50 mg daily tablet is the established oral dose for oncology patients. Clinical trials have demonstrated that this dose effectively reduces the rate of skeletal events when taken consistently. Treatment should continue for as long as clinical benefit is maintained, as determined by your oncologist.
Bone Metastases from Breast Cancer (Intravenous Alternative)
Dose: 6 mg administered as an intravenous infusion over at least 15 minutes every 3–4 weeks. The IV route may be preferred for patients who cannot tolerate or comply with oral dosing requirements, or who have significant gastrointestinal disorders.
How to Take Bondronat Correctly
The way you take Bondronat is critically important for both effectiveness and safety. Following these instructions carefully will ensure the medication reaches your stomach quickly and reduces the risk of esophageal irritation:
- Take it first thing in the morning: After waking up and before eating, drinking, or taking any other medication, swallow the tablet whole with a full glass of plain tap water (at least 200 ml / 7 fl oz).
- Do not use mineral water (still or sparkling), coffee, tea, juice, or milk — these can reduce absorption.
- Do not chew, crush, suck, or dissolve the tablet — swallow it whole to avoid local irritation of the mouth or upper esophagus.
- Stay upright for 60 minutes: After swallowing the tablet, remain sitting or standing for at least 60 minutes. Do not lie down during this time.
- Wait before eating or taking other medicines: Do not eat, drink, or take any other medication (including antacids, calcium, vitamins, and chemotherapy pills) for at least 60 minutes after taking Bondronat.
- Do not take at bedtime or before getting up for the day.
Elderly Patients
No dose adjustment is required for elderly patients. However, because renal function often declines with age, kidney function should be monitored periodically. Elderly patients may also be at increased risk of gastrointestinal side effects and should be particularly careful to follow the dosing instructions precisely. Falls risk should be assessed, as concurrent bisphosphonate use with frailty in elderly oncology patients warrants additional attention.
Renal Impairment
Dose Adjustments for Kidney Function
Mild impairment (CrCl > 50 ml/min): No dose adjustment required.
Moderate impairment (CrCl 30–50 ml/min): Dose reduction to 50 mg every other day is recommended according to the EMA SmPC.
Severe impairment (CrCl < 30 ml/min): Bondronat is contraindicated.
Missed Dose
If you forget to take your daily Bondronat tablet, do not take a double dose to make up for the missed one. Simply skip the missed dose and take your next tablet as usual the following morning. Taking a double dose increases the risk of esophageal and gastrointestinal side effects without providing additional benefit.
Overdose
If you accidentally take too many Bondronat tablets, drink a full glass of milk and contact a doctor or poison control center immediately. Do not induce vomiting and do not lie down — vomiting or lying down could worsen esophageal damage. Overdose may cause low blood calcium (hypocalcemia), low blood phosphate (hypophosphatemia), and upper gastrointestinal adverse events such as stomach upset, heartburn, esophagitis, gastritis, or ulcer. In cases of significant overdose, treatment is supportive: milk or antacids to bind ibandronic acid, correction of electrolyte imbalances, and monitoring of renal function.
What Are the Side Effects of Bondronat?
Like all medicines, Bondronat can cause side effects, although not everyone gets them. It is important to understand that many patients with breast cancer and bone metastases experience symptoms from their underlying disease and other concurrent treatments (chemotherapy, radiotherapy, hormonal therapy), which can overlap with bisphosphonate side effects. Your oncology team will help distinguish between drug-related and disease-related symptoms.
- Difficulty swallowing or pain when swallowing
- Chest pain or new/worsening heartburn
- Severe allergic reactions (hives, swelling of face, lips, tongue, or throat, difficulty breathing)
- Pain in the mouth, jaw, or teeth; jaw swelling or numbness; loose teeth; exposed bone in the mouth
- Unusual pain, weakness, or discomfort in the thigh, hip, or groin (may indicate an atypical femur fracture)
- Severe skin reactions (blistering, peeling skin)
- Eye problems: pain, redness, blurred vision, light sensitivity (may indicate uveitis or scleritis)
Side Effect Frequency
Very Common
- Bone pain, musculoskeletal pain
- Nausea
- Fatigue
Common
- Diarrhea, abdominal pain, dyspepsia (indigestion)
- Headache, dizziness
- Hypocalcemia (low blood calcium)
- Joint pain, back pain, muscle pain
- Flu-like symptoms (fever, chills, malaise) — especially during the first days of treatment
- Vomiting, constipation, flatulence
- Esophagitis, difficulty swallowing, heartburn
- Tooth disorder
- Anemia
Uncommon
- Esophageal stricture, esophageal ulcer
- Urinary tract infection
- Hypersensitivity reactions, angioedema
- Paresthesia (tingling or numbness)
- Taste disturbance (dysgeusia)
- Uveitis, scleritis, or episcleritis (eye inflammation)
- Increased liver enzymes (transaminases)
Rare
- Osteonecrosis of the jaw (ONJ) — exposed bone in the jaw that fails to heal
- Atypical femoral fractures — unusual fractures of the thigh bone with minimal or no trauma
- Stevens-Johnson syndrome / toxic epidermal necrolysis (severe skin reactions)
- Osteonecrosis of the external auditory canal
Very Rare
- Anaphylactic reaction / anaphylactic shock
- Bronchospasm in aspirin-sensitive patients
Flu-Like Reactions
Some patients experience a flu-like reaction (also called an acute phase response) during the first few days after starting Bondronat, particularly with the IV formulation but also possible with oral tablets. Symptoms include fever, chills, muscle aches, joint pain, headache, and malaise. These reactions are generally mild, self-limiting, and typically resolve within 24–48 hours. They are less common with subsequent doses and can be managed with paracetamol (acetaminophen) or ibuprofen if tolerated.
Monitoring During Treatment
Your oncology team will typically monitor the following during Bondronat treatment:
- Renal function (serum creatinine, estimated GFR) — before starting treatment and periodically thereafter
- Serum calcium and phosphate — particularly in the early weeks of treatment and in patients at risk of hypocalcemia
- Vitamin D levels — deficiency should be corrected with supplementation
- Dental health — regular dental assessments with attention to signs of ONJ
- Bone pain and skeletal events — to assess treatment efficacy and inform ongoing management decisions
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed above. You can also report side effects directly through your national adverse drug reaction reporting system (for example, the Yellow Card Scheme in the UK, MedWatch in the US, or EudraVigilance in the EU). By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Bondronat?
Proper storage of medications is essential to ensure that they remain effective and safe throughout the prescribed treatment period. Bondronat should be stored under the following conditions:
- Temperature: Store below 25°C (77°F). Do not freeze.
- Protection: Keep the tablets in the original blister packaging to protect from moisture and light.
- Accessibility: Keep this medicine out of the sight and reach of children. Store in a secure location, particularly if other household members are not prescribed this medication.
- Expiry: Do not use Bondronat after the expiry date which is stated on the blister and the carton after “EXP.” The expiry date refers to the last day of that month.
Do not dispose of unused medicines via household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment and ensure that medications are disposed of safely. Many pharmacies and healthcare facilities offer take-back programs for unused medications.
What Does Bondronat Contain?
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical ingredients. Below is a detailed breakdown of what Bondronat tablets contain:
Active Ingredient
Each film-coated tablet contains 50 mg ibandronic acid (as 56.25 mg ibandronate sodium monohydrate). Ibandronic acid is the therapeutically active substance — a nitrogen-containing bisphosphonate with the chemical formula C9H23NO7P2. It is a white to off-white crystalline powder that is highly water-soluble.
Inactive Ingredients (Excipients)
The tablet core and film-coating contain the following excipients:
- Tablet core: Lactose monohydrate, povidone K25, microcrystalline cellulose, crospovidone, stearic acid, colloidal anhydrous silica
- Film-coating: Hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E171), talc, macrogol 6000
The tablet is a white to off-white, oblong, film-coated tablet. The film-coating helps the tablet to be swallowed more easily and protects the active ingredient from moisture.
Bondronat tablets contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, or if you have a rare hereditary problem of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption, contact your doctor before taking this medicine. The amount of lactose per tablet is relatively small, but may be clinically relevant for patients with severe lactose intolerance.
Frequently Asked Questions About Bondronat
Both Bondronat and Bonviva (called Boniva in the US) contain the same active ingredient — ibandronic acid — but they are used for different conditions and at different doses. Bondronat 50 mg daily is specifically indicated for the prevention of skeletal events in breast cancer patients with bone metastases. Bonviva/Boniva is used for postmenopausal osteoporosis at a dose of 150 mg once monthly (oral) or 3 mg every 3 months (IV). The key difference is the indication, dose, and dosing frequency.
Ibandronic acid has an extremely low oral bioavailability of approximately 0.6% even under fasting conditions. Any food, drink (other than plain water), or medication taken at the same time can virtually eliminate absorption. The 60-minute fasting window for the Bondronat 50 mg oncology dose (compared to 30 minutes for some other bisphosphonates) is necessary because the daily dosing means consistent, reliable absorption each day is critical for maintaining therapeutic drug levels. Lying down during this period also risks the tablet lodging in the esophagus and causing local damage.
No. Bondronat is not a treatment for cancer itself and does not eliminate bone metastases. Its role is supportive — it reduces the rate of skeletal complications (fractures, need for radiation therapy to bone, spinal cord compression) caused by bone metastases. By slowing down the excessive bone breakdown driven by metastatic tumor cells, Bondronat helps to preserve bone integrity and improve quality of life. Your anti-cancer treatment (chemotherapy, hormonal therapy, targeted therapy) addresses the cancer directly.
Jaw pain, swelling, numbness, a feeling of heaviness in the jaw, loose teeth, or exposed bone in the mouth may be signs of osteonecrosis of the jaw (ONJ), a rare but serious side effect. Contact your oncologist or dentist promptly if you experience any of these symptoms. Do not undergo elective dental surgery (particularly tooth extractions) without first discussing your bisphosphonate use with your dental professional. ONJ is more common in cancer patients, particularly those also receiving chemotherapy, corticosteroids, or anti-angiogenic therapy.
Yes, in most cases. Your oncologist will typically recommend calcium and vitamin D supplementation during Bondronat treatment, because bisphosphonates can cause hypocalcemia (low blood calcium), and patients with bone metastases may already have disrupted calcium metabolism. However, do not take calcium supplements at the same time as Bondronat — wait at least 60 minutes after your Bondronat tablet before taking calcium. Vitamin D supplementation is especially important if you have documented vitamin D deficiency, limited sun exposure, or are taking medications that affect vitamin D metabolism.
All information is based on international medical guidelines and peer-reviewed research: the EMA Summary of Product Characteristics (SmPC) for Bondronat, ESMO Clinical Practice Guidelines for bone metastases, ASCO guidelines for bone-modifying agents in metastatic breast cancer, Cochrane reviews on bisphosphonates for breast cancer, FDA approved labeling, and the British National Formulary (BNF). All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomized controlled trials.
References
- European Medicines Agency (EMA). Bondronat — Summary of Product Characteristics. Last updated 2024. Available from: EMA product information database.
- Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology. 2003;14(9):1399–1405.
- Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004;111(3):306–312.
- Cochrane Database of Systematic Reviews. Bisphosphonates for breast cancer. 2022. doi:10.1002/14651858.CD003474.pub4.
- ESMO Clinical Practice Guidelines. Bone health in cancer: ESMO–EAPC Clinical Practice Guideline. Annals of Oncology. 2020;31(12):1650–1663.
- Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer. Journal of Clinical Oncology. 2011;29(9):1221–1227.
- World Health Organization. WHO Model List of Essential Medicines. 23rd list (2023). Geneva: WHO; 2023.
- British National Formulary (BNF). Ibandronic acid. National Institute for Health and Care Excellence (NICE). Accessed January 2026.
- Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. Journal of Bone and Mineral Research. 2015;30(1):3–23.
- Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research. 2014;29(1):1–23.
Editorial Team
This article was written by the iMedic Medical Editorial Team, comprising licensed specialist physicians in clinical pharmacology, oncology, and bone metabolism. All content follows the GRADE evidence framework and adheres to international medical guidelines from the EMA, FDA, WHO, ESMO, and ASCO.
Our editorial process includes:
- Systematic literature review of peer-reviewed sources
- Medical review by board-certified specialists
- Regular updates to reflect new evidence and guideline changes
- Strict independence from pharmaceutical industry funding
Last reviewed: . For questions about our editorial standards, visit our editorial standards page.